|
1
|
Negro F: Abnormalities of lipid metabolism
in hepatitis C virus infection. Gut. 59:1279–1287. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Cacoub P, Comarmond C, Domont F, Savey L,
Desbois AC and Saadoun D: Extrahepatic manifestations of chronic
hepatitis C virus infection. Ther Adv Infect Dis. 3:3–14.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ferri C, Sebastiani M, Giuggioli D, Colaci
M, Fallahi P, Piluso A, Antonelli A and Zignego AL: Hepatitis C
virus syndrome: A constellation of organ- and non-organ specific
autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer.
World J Hepatol. 7:327–343. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Syed GH, Amako Y and Siddiqui A: Hepatitis
C virus hijacks host lipid metabolism. Trends Endocrinol Metab.
21:33–40. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Chayama K, Takahashi S, Toyota J, Karino
Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E and Kumada
H: Dual therapy with the nonstructural protein 5A inhibitor,
daclatasvir, and the nonstructural protein 3 protease inhibitor,
asunaprevir, in hepatitis C virus genotype 1b-infected null
responders. Hepatology. 55:742–748. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wang HL, Lu X, Yang X and Xu N:
Effectiveness and safety of daclatasvir plus asunaprevir for
hepatitis C virus genotype 1b: Systematic review and meta-analysis.
J Gastroenterol Hepatol. 32:45–52. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chang ML, Tsou YK, Hu TH, Lin CH, Lin WR,
Sung CM, Chen TH, Cheng ML, Chang KC, Chiu C, et al: Distinct
patterns of the lipid alterations between genotype 1 and 2 chronic
hepatitis C patients after viral clearance. PLoS One.
9(e104783)2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Younossi ZM, Stepanova M, Estep M, Negro
F, Clark PJ, Hunt S, Song Q, Paulson M, Stamm LM, Brainard DM, et
al: Dysregulation of distal cholesterol biosynthesis in association
with relapse and advanced disease in CHC genotype 2 and 3 treated
with sofosbuvir and ribavirin. J Hepatol. 64:29–36. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Meissner EG, Lee YJ, Osinusi A, Sims Z,
Qin J, Sturdevant D, McHutchison J, Subramanian M, Sampson M,
Naggie S, et al: Effect of sofosbuvir and ribavirin treatment on
peripheral and hepatic lipid metabolism in chronic hepatitis C
virus, genotype 1-infected patients. Hepatology. 61:790–801.
2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hashimoto S, Yatsuhashi H, Abiru S,
Yamasaki K, Komori A, Nagaoka S, Saeki A, Uchida S, Bekki S,
Kugiyama Y, et al: Rapid increase in serum low-density lipoprotein
cholesterol concentration during hepatitis C interferon-free
treatment. PLoS One. 11(e0163644)2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem
S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A,
Zhou Y, et al: Treatment of HCV infection by targeting microRNA. N
Engl J Med. 368:1685–1694. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Esau C, Davis S, Murray SF, Yu XX, Pandey
SK, Pear M, Watts L, Booten SL, Graham M, McKay R, et al: miR-122
regulation of lipid metabolism revealed by in vivo antisense
targeting. Cell Metab. 3:87–98. 2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Miyaaki H, Ichikawa T, Kamo Y, Taura N,
Honda T, Shibata H, Milazzo M, Fornari F, Gramantieri L, Bolondi L
and Nakao K: Significance of serum and hepatic microRNA-122 levels
in patients with non-alcoholic fatty liver disease. Liver Int.
34:e302–e307. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Cunningham D, Danley DE, Geoghegan KF,
Griffor MC, Hawkins JL, Subashi TA, Varghese AH, Ammirati MJ, Culp
JS, Hoth LR, et al: Structural and biophysical studies of PCSK9 and
its mutants linked to familial hypercholesterolemia. Nat Struct Mol
Biol. 14:413–419. 2007.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Labonté P, Begley S, Guévin C, Asselin MC,
Nassoury N, Mayer G, Prat A and Seidah NG: PCSK9 impedes hepatitis
C virus infection in vitro and modulates liver CD81 expression.
Hepatology. 50:17–24. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Syed GH, Tang H, Khan M, Hassanein T, Liu
J and Siddiqui A: Hepatitis C virus stimulates low-density
lipoprotein receptor expression to facilitate viral propagation. J
Virol. 88:2519–2529. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bridge SH, Sheridan DA, Felmlee DJ,
Crossey MM, Fenwick FI, Lanyon CV, Dubuc G, Seidah NG, Davignon J,
Thomas HC, et al: PCSK9, apolipoprotein E and lipoviral particles
in chronic hepatitis C genotype 3: evidence for genotype-specific
regulation of lipoprotein metabolism. J Hepatol. 62:763–770.
2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Matthews DR, Hosker JP, Rudenski AS,
Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment:
Insulin resistance and beta-cell function from fasting plasma
glucose and insulin concentrations in man. Diabetologia.
28:412–419. 1985.PubMed/NCBI
|
|
19
|
Asano T, Kawamura M, Watanabe T, Abe M,
Chin R, Miyazaki S and Hirata Y: Indices of urinary and serum
C-peptide corrected with fasting plasma glucose for decision-making
of insulin therapy in type 2 diabetes-validation and comparison. J
Jpn Diabetes Soc. 51:759–763. 2008. View Article : Google Scholar
|
|
20
|
DeLong DM, DeLong ER, Wood PD, Lippel K
and Rifkind BM: A comparison of methods for the estimation of
plasma low- and very low-density lipoprotein cholesterol. The Lipid
Research Clinics Prevalence Study. JAMA. 256:2372–2377.
1986.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hori M, Ishihara M, Yuasa Y, Makino H,
Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H and
Harada-Shiba M: Removal of plasma mature and furin-cleaved
proprotein convertase subtilisin/kexin 9 by low-density
lipoprotein-apheresis in familial hypercholesterolemia: Development
and application of a new assay for PCSK9. J Clin Endocrinol Metab.
100:E41–E49. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sohn W, Kim J, Kang SH, Yang SR, Cho JY,
Cho HC, Shim SG and Paik YH: Serum exosomal microRNAs as novel
biomarkers for hepatocellular carcinoma. Exp Mol Med.
47(e184)2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Negro F and Sanyal AJ: Hepatitis C virus,
steatosis and lipid abnormalities: clinical and pathogenic data.
Liver Int. 29 (Suppl 2):26–37. 2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Rotllan N, Price N, Pati P, Goedeke L and
Fernández-Hernando C: microRNAs in lipoprotein metabolism and
cardiometabolic disorders. Atherosclerosis. 246:352–360.
2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lanford RE, Hildebrandt-Eriksen ES, Petri
A, Persson R, Lindow M, Munk ME, Kauppinen S and Ørum H:
Therapeutic silencing of microRNA-122 in primates with chronic
hepatitis C virus infection. Science. 327:198–201. 2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kamo Y, Ichikawa T, Miyaaki H, Uchida S,
Yamaguchi T, Shibata H, Honda T, Taura N, Isomoto H, Takeshima F
and Nakao K: Significance of miRNA-122 in chronic hepatitis C
patients with serotype 1 on interferon therapy. Hepatol Res.
45:88–96. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Machlin ES, Sarnow P and Sagan SM: Masking
the 5' terminal nucleotides of the hepatitis C virus genome by an
unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S
A. 108:3193–3198. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Shimakami T, Yamane D, Jangra RK, Kempf
BJ, Spaniel C, Barton DJ and Lemon SM: Stabilization of hepatitis C
virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci U S A.
109:941–946. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Pedersen IM, Cheng G, Wieland S, Volinia
S, Croce CM, Chisari FV and David M: Interferon modulation of
cellular microRNAs as an antiviral mechanism. Nature. 449:919–922.
2007.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sarasin-Filipowicz M, Krol J, Markiewicz
I, Heim MH and Filipowicz W: Decreased levels of microRNA miR-122
in individuals with hepatitis C responding poorly to interferon
therapy. Nat Med. 15:31–33. 2009.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Benjannet S, Rhainds D, Hamelin J,
Nassoury N and Seidah NG: The proprotein convertase (PC) PCSK9 is
inactivated by furin and/or PC5/6A: Functional consequences of
natural mutations and post-translational modifications. J Biol
Chem. 281:30561–30572. 2006.PubMed/NCBI
|
|
33
|
Lagace TA: PCSK9 and LDLR degradation:
Regulatory mechanisms in circulation and in cells. Curr Opin
Lipidol. 25:387–393. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Girona J, Ibarretxe D, Plana N,
Guaita-Esteruelas S, Amigo N, Heras M and Masana L: Circulating
PCSK9 levels and CETP plasma activity are independently associated
in patients with metabolic diseases. Cardiovasc Diabetol.
15(107)2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wang S, Cheng ZY, Zhao ZN, Quan XQ, Wei Y,
Xia DS, Li JQ and Hu JL: Correlation of serum PCSK9 in CHD patients
with the severity of coronary arterial lesions. Eur Rev Med
Pharmacol Sci. 20:1135–1139. 2016.PubMed/NCBI
|
|
36
|
Ruscica M, Ferri N, Macchi C, Meroni M,
Lanti C, Ricci C, Maggioni M, Fracanzani AL, Badiali S, Fargion S,
et al: Liver fat accumulation is associated with circulating PCSK9.
Ann Med. 48:384–391. 2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Tamada M, Makita S, Abiko A, Naganuma Y,
Nagai M and Nakamura M: Low-density lipoprotein cholesterol to
high-density lipoprotein cholesterol ratio as a useful marker for
early-stage carotid atherosclerosis. Metabolism. 59:653–657.
2010.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Miyajima I, Kawaguchi T, Fukami A, Nagao
Y, Adachi H, Sasaki S, Imaizumi T and Sata M: Chronic HCV infection
was associated with severe insulin resistance and mild
atherosclerosis: A population-based study in an HCV hyperendemic
area. J Gastroenterol. 48:93–100. 2013.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Negro F: Facts and fictions of HCV and
comorbidities: Steatosis, diabetes mellitus, and cardiovascular
diseases. J Hepatol. 61 (Suppl 1):S69–S78. 2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Shen H, Xu L, Lu J, Hao T, Ma C, Yang H,
Lu Z, Gu Y, Zhu T and Shen G: Correlation between small dense
low-density lipoprotein cholesterol and carotid artery intima-media
thickness in a healthy Chinese population. Lipids Health Dis.
14(137)2015.PubMed/NCBI View Article : Google Scholar
|
